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cyclosporine Metabolite Profiles in the Blood of Liver 
Transplant Patients 
C.P. Wang. G.J. Burckart, R. Venkataramanan, R.J. Ptachcinski, R.E. Cuellar, L. Makowka, 
D.H. Van Thiel. and T.E. Starzl 
CYCLOSPORINE (CyA) is a potent immunosuppressive agent that under-
goes extensive hepatic metabolism. Eleven 
metabolites of CyA have been fully character-
ized. 1 Recent reports indicate that CyA 
metabolites have in vitro immunosuppressive 
activity and/or nephrotoxicity.2.4 The time 
course of the formation and elimination of 
these metabolites in the blood of transplant 
patients has not been documented, however. 
The objective of our study, therefore, was to 
quantitate four major CyA metabolites in the 
blood of liver transplant patients over a dosing 
interval after oral and intravenous CyA 
administra tion . 
MATERIALS AND METHODS 
Patients 
Three adult liver transplant patients who were c1ini-
Cllh stable. on the basis of serum bilirubin and liver 
cnl~me levels. were enrolled in the study. Blood sampling 
..as conducted on two consecutive days: after the patient's 
oral CyA dose on the first day and after an intravenous 
CyA dose that was 50% of the oral dose on the second day. 
Hourly blood samples were obtained during the 12-hour 
dosing interval on both study days. 
Measurement ojCyA and Metabolites 
The measurement of CyA and metabolite concentra-
tions used a gradient high-performance liquid chromato-
graphic (HPLC) system. The column was a Resolve 
C-18. 15 cm x 3.9 mm. 5-l'm column (Waters. Milford. 
MA) that was heated to 70°C. The mobile phase con-
sisted of a linear gradient of acetonitrile and water 
delivered at 1.0 mL/min. Two milliliters of whole blood 
\lias mixed with an internal standard (cyclosporine D) and 
extracted with diethyl ether. The final dried extract was 
reconstituted in 100 I'L methanol. and 40 I'L was injected 
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Table 1. Blood Concentrations of CyA end Metabolites in liver Transplant Patients 
Average ConcentratlOn° Ing/mU Range 
Route IDose. mg/kgi CVA M17 M1 M1S M21 
Pat,ent 1 
IV(2.9) 1.253 1.200 369 161 161 
(203-3.271 ) (441-1.570) (109-485) (57-223) (53-286) 
PO(5.7) 808 1.301 544 213 202 
(356-1.578) (550-1.860) ( 117-898) (38-349) (41-364) 
Patient 2 
IV (1.7) 593 860 226 91 72 
(203-1.537) (601-1.358) ( 115-297) (44-186) (32-136) 
PO (3.5) 364 648 238 86 46 
(232-571) (535-1.349) (125-480) (56-203) (41-145) 
Patient 3 
IV(2.2) 695 647 279 53 66 
( 170-2.306) (434-860) ( 153-412) «25-86) 1<25-141) 
PO (4.4) 393 464 280 24 52 
(235-635) (344-660) ( 81-542) 1<25-59) 1<25-183) 
AbbreVIations: IV. intravenous: PO. oral. 
° Average steady-state concentration lep·) calculated as area under the curve divided by the dosing Interval. 
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onlO the HPLC column. Standards of the metabolites 
(M 17, M I. M I H, M 21) were prepared from material 
recovered from human bile and confirmed by HPLC and 
mass spectrometry. Standard curves were prepared for 
CyA and each of the four metabolites that were quanti-
fied. 
RESULTS 
The average and range of blood concentra-
tions observed during the dosing interval are 
presented in Table I. Figure I demonstrates 
the typical metabolite concentrations mea-
sured over time during the dosing interval. 
The blood concentrations for the three 
patients were M 17 > CyA > MI for the oral 
12 
Fig 1. eyA and matabolita blood concantra-
tions aftar livar transplantation. 
study, whereas M 18 and M 21 concentrations 
varied during the dosing interval. In the intra-
venous study, the blood concentrations were 
CyA > M 17 > M I in two patients, with the 
third patient following the oral pattern. 
Metabolite concentrations did not consistently 
decline over the dosing interval; the CyA and 
metabolite concentrations increased to their 
highest level between nine and 12 hours in the 
oral study of patient no. 2. 
DISCUSSION 
High concentrations of CyA metabolites, 
particularly M 17 and M I. were present in the 
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concentrations was observed. The late 
increase in metabolite conccntrations in the 
oral dosing interval of patient 2 may be due to 
either altered CyA absorption or metabolism. 
Additional studies are necessary to evaluate 
the immunosuppressive or toxic effects of 
these high concentrations of blood metabolites 
in liver transplant pa tients. 
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